Clinical Trial Update: MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial update on MultiStem administration for COVID-19-induced ARDS (MACoVIA) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• MultiStem (mesenchymal-like stem cell product)

Snippet

Sponsor: Healios K.K. | Conditions: ARDS | Phase 2, Phase 3 | Status: UNKNOWN